Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease

Annals of the New York Academy of Sciences

Volumn 893, Issue , 1999, Pages 176-191

  Ghosh, Soumitra S ^a   Swerdlow, Russell H ^b   Miller, Scott W ^a   Sheeman, Brina ^a   Parker Jr , W Davis ^b   Davis, Robert E ^a  

^a Migenix Inc   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA;

ALZHEIMER DISEASE; CALCIUM HOMEOSTASIS; CELL LINE; CONFERENCE PAPER; HOST CELL; HUMAN; HYBRID CELL; MITOCHONDRION; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; RESPIRATORY CHAIN; THROMBOCYTE;

EID: 0033392047     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07825.x     Document Type: Conference Paper

References (72)

1. 1. Fiskum, G., A.N. Murphy & M.F. Beal. 1999. Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. J. Cereb. Blood Flow Metab. 19: 351-369.
2. 2. Howell, N. 1997. Leber hereditary optic neuropathy: how do mitochondrial DNA mutations cause degeneration of the optic nerve? J. Bioenerg. Biomembr. 29: 165-173.
3. 3. Howell, N. 1998. Leber hereditary optic neuropathy: respiratory chain dysfunction and ration of the optic nerve. Vision Res. 38: 1495-1504.
4. 4. a. King, M.P. & G. Attardi. 1989. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246: 500-503. b. king, M.P. & G. Attardi. 1989. Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA. Cell 52: 811-819.
5. 4. a. King, M.P. & G. Attardi. 1989. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246: 500-503. b. king, M.P. & G. Attardi. 1989. Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA. Cell 52: 811-819.
6. 5. Chomyn, A., S.T. Lai, R. Shakeley, N. Bresolin, G. Scarlato & G. Attardi. 1994. Platelet-mediated transformation of mtDNA-less human cells: analysis of phenotypic variability among clones from normal individuals and complementation behavior of the tRNAlys mutation causing myoclonic epilepsy and ragged red fibers. Am. J. Hum. Genet. 54: 966-974.
7. 6. Kuhl, D.E., E.J. Metter & W.H. Riege. 1985. Patterns of cerebral glucose utilization in depression, multiple infarct dementia, and Alzheimer's disease. Res. Publ. Assoc. Nerv. Ment. Dis. 63: 211-226.
8. 7. Haxby, J.V., C.L. Grady, E. Koss, B. Horwitz, L. Heston, M. Schapir, R.P. Friedland & S.I. Rapoport. 1990. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch. Neurol. 47: 753-760.
9. 8. Azari, N.P., K.D. Pettigrew, M.B. Schapiro, J.V. Haxby, C.L. Grady, P. Pietrini, J.A. Salerno, L.L. Heston, S.I. Rapoport & B. Horwitz. 1993. Early detection of Alzheimer's disease: a statistical approach using positron emission tomography. J. Cereb. Blood Flow Metab. 13: 438-447.
10. 9. Palmer, A.M. & M.A. Burns. 1994. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 645: 338-342.
11. 10. Pappolla, M.A., R.A. Omar, K.S. Kim & N.K. Robakis. 1992. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am. J. Pathol. 140: 621-628.
12. 11. Jeandel, C., M.B. Nicolas, F. Dubois, F. Nabet-Belleville, F. Penin & G. Cuny. 1989. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 35: 275-282.
13. 12. Balazs, L. & M. Leon. 1994. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem. Res. 19: 1131-1137.
14. 13. Mecocci, P., U. MacGarvey & M.F. Beal. 1994. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36: 747-751.
15. 14. Smith, M.A., G. Perry, P.L. Richey, L.M. Sayre, V.M. Anderson, M.F. Beal & N. Kowall. 1996. Oxidative damage in Alzheimer's Disease. Nature 382: 120-121.
16. 15. Pettegrew, J.W., W.E. Klunk, K. Panchalingam, J.N. Kanfer & R.J. McClure. 1994. Alterations of cerebral metabolism in probable Alzheimer's disease. Neurobiol. Aging 15: 117-132.
17. 16. Pettegrew, J.W., W.E. Klunk, E. Kanal, K. Panchalingam & R.J. McClure. 1995. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol. Aging 16: 973-975.
18. 17. Duara, R., R.F. Lopez-Alberola, W.W. Barker, D.A. Loewenstein, M. Zatinsky, C.E. Eisdorfer & G.B. Weinberg. 1993. A comparison of familial and sporadic Alzheimer's disease. Neurology 43: 1377-1384.
19. 18. Edland, S.D., J. Silverman, E.R. Peskind, D. Tsaung, E. Wijsman & J.C. Morris. 1996. Increased risk of dementia in mothers of Alzheimers disease cases: evidence for maternal inheritance. Neurology 47: 254-256.
20. 19. Parker, W.D., C.M. Filley & J.K. Parks. 1990. Cytochrome oxidase deficiency in Alzheimers disease. Neurology 40: 1320-1303.
21. 20. Kish, S.J., C. Bergeron, A. Rajput, S. Dozic, F. Mastrogiacomo, L.J. Chang, J.M. Wilson, L.M. Distefano & J.N. Nobrega. 1992. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 59: 776-779.
22. 21. Parker, W.D., J.K. Parks, C.M. Filley & B.K. Kleinschmidt-Demasters. 1994. Electron transport chain defects in Alzheimer's disease. Neurology 44: 1090-1096.
23. 22. Parker, JR., W.D., N.J. Mahr & C.M. Filley. 1994. Reduced platelet cytochrome oxidase activity in Alzheimers disease. Neurology 44: 1086-1090.
24. 23. Mutisya, E.M., A.C. Bowling & M.F. Beal. 1994. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63: 2179-2184.
25. 24. Chagnon, P., C. Betard, Y. Robitaille, A. Cholette & D. Gauvreau. 1995. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. NeuroReport 6: 711-715.
26. 25. Parker, JR., W.D. & J.K. Parks. 1995. Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 45: 482-486.
27. 26. Miller, S.W., P.A. Trimmer, W.D. Parker, JR. & R.E. Davis. 1996. Creation and characterization of mitochondrial DNA depleted cell lines with "neuronal-like" properties. J. Neurochem. 67: 1897-1907.
28. 27. Swerdlow, R.H., J.K. Parks, B.S. Cassarino, D.J. Maguire, R.S. Maguire, J.P. Bennett, R.E. Davis & W.D. Parker, JR. 1997. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 49: 918-925.
29. 28. Ghosh, S.S., S.E. Miller, C. Herrnstadt, J.A. Dykens, A.N. Murphy & R.E. Davis. 1999. Genetic and biochemical characterization of a cybrid cell line with a stable cytochrome c oxidase defect. Soc. Neurosci. Abstr. 25(1): 337.
30. 29. Davis, R.E., S. Miller, C. Herrnstadt, S.S. Ghosh, E. Fahy, L.E. Shinobu, D. Galasko, L.J. Thal., M.F. Beal, N. Howell & W.D. Parker, JR. 1997. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease Proc. Natl. Acad. Sci. USA 94: 4526-4531.
31. 30. Dunbar, D.R., P.A. Moonie, H.T. Jacobs & I.J. Holt. 1995. Different cellular backgrounds confer a marked advantage to either mutant or wild-type mitochondrial genomes. Proc. Natl. Acad. Sci. USA 92: 6562-6566.
32. 2 in cultured endothelial cells. Arch. Biochem. Biophys. 302: 348-355.
33. 32. Sheehan, J.P., R.H. Swerdlow, S.W. Miller, R.E. Davis, J.K. Parks, W.D. Parker & J.B. Tuttle. 1997. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J. Neurosci. 17: 4612-4622.
34. 33. Trimmer, P.A., R.H. Swerdlow, J.K. Parks, S.W. Miller, R.E. Davis & W.D. Parker, JR. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid lines. Exp. Neurol. In press.
35. 34. Langston, J.W., P.A. Ballard, J.W. Tetrud & I. Irwin. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
36. 35. Nicklas, W.J., I. Vyas & R.E. Heikkila. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36: 2503-2508.
37. 36. Parker, W.D., S.J. Boyson & J.K. Parks. 1989. Electron transport chain abnormalities in idiopathic Parkinson's disease. Ann. Neurol. 26: 719-723.
38. 37. Schapira, A.H.V., J.M. Cooper, D. Dexter, P. Jenner, J.B. Clark & C.D. Marsden. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1289.
39. 38. Mizuno, Y., S. Ohta, M. Tanaka, S. Takamiya, K. Suzuki, T. Sato, H. Oya, T. Ozawa & Y. Kagawa. 1989. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163: 1450-1455.
40. 39. Parker, W.D. 1990. Sporadic neurologic disease and the electron transport chain: a hypothesis. In Proceedings of the 1989 Meeting of the American Society for Neurologic Investigation: New Developments in Neuromuscular Disease. R.M. Pascuzzi, Ed.: 59-64. Indiana University Printing Services. Bloomington.
41. 40. Schapira, A.H.V., I.J. Holt, M. Sweeney, A.E. Harding, P. Jenner & C.D. Marsden. 1990. Mitochondrial DNA analysis in Parkinson's disease. Movement Disorders 5: 294-297.
42. 41. Lestienne, P., J. Nelson, P. Riederer, K. Jellinger & H. Reichmann. 1990. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J. Neurochem. 55: 1810-1812.
43. 42. Lestienne, P., I. Nelson, P. Reiderer, H. Reichmann & K. Jellinger. 1991. Mitochondrial DNA in postmortem brain from patients with Parkinson's disease. J. Neurochem. 56: 1819.
44. 43. Mann, V.M., J.M. Cooper & A.H.V. Schapira. 1992. Quantitation of a mitochondrial DNA deletion in Parkinson's disease. FEBS Lett. 299: 218-222.
45. 44. Sandy, M.S., J.W. Langston, M.T. Smith & D.A. Di Monte. 1993. PCR analysis of platelet mtDNA: lack of specific changes in Parkinson's disease. Movement Disorders 8: 74-82.
46. 45. DiDonato, S., M. Zeviani, P. Giovannini, N. Savarese, M. Rimoldi, C. Mariotti, F. Girotti & T. Caraceni. 1993. Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology 43: 2262-2268.
47. 46. Swerdlow, R.H., J.K. Parks, S.W. Miller, J.B. Tuttle, P.A. Trimmer, J.P. Sheehan, J.P. Bennett, R.E. Davis & W.D. Parker. 1996. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40: 663-671.
48. 47. Krige, D., M.T. CARROL, J.M. Cooper, C.D. Marsden & A.H.V. Schapira. 1992. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann. Neurol. 32: 782-788.
49. 48. Yoshino, H., Y. Nakagawa-Hattori, T. Kondo & Y. Mizuno. 1992. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural Transm. 41: 27-34.
50. 49. Benecke, R., P. Strumper & H. Weiss. 1993. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 116: 1451-1455.
51. 50. Haas, R.H., F. Nasirian, K. Nakano, D. Ward, M. PAY, R. Hill & C.W. Shults. 1995. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37: 714-722.
52. 51. Gu, M., J.M. Cooper, J.W. Taanman & A.H.V. Schapira. 1998. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol. 44: 177-186.
53. 52. Shults, C.W. & S.W. Miller. 1998. Reduced complex I activity in parkinsonian cybrids. Movement Disorders 13 (Suppl. 2): 217.
54. 53. Tabrizi, S.J., J.M. Cooper & A.H.V. Schapira. 1998. Mitochondrial DNA in focal dystonia: a cybrid analysis. Ann. Neurol. 44: 258-261.
55. 54. Swerdlow, R.H., J.K. Parks, M.B. Harrison & W.D. Parker. 1999. Normal electron transport chain activities in Huntington's cybrids. Soc. Neurosci. Abstr. 24(1): 476.
56. 55. Caldwell, S.H., R.H. Swerdlow, E.M. Kahn, J.C. Iezzoni, E.E. Hespeneide, J.K. Parks & W.D. Parker, JR. 1999. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 31: 430-434.
57. 56. Golbe, L.I., G. Di Iorio, V. Bonavita, D.C. Miller & R.C. Duvoisin. 1990. A large kindred with autosomal dominant Parkinson's disease. Ann. Neurol. 27: 276-282.
58. 57. Polymeropoulos, M.H., C. Lavedan, E. Leroy, S.E. IDE, A. Dehajia, A. Dutra, B. Pike, H. Root, J. Rubinstein, R. Boyer, E.S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropolous, W.G. Johnson, A.M. Lazzarini, R.C. Duvoisin, G. Di Iorio, L.I. Golbe & R.L. Nussbaum. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
59. 58. Parker, W.D., L.I. Golbe, J.K. Parks, G. Di Iorio, G.F. Wooten & R.H. Swerdlow. 1999. Cybrid analysis of Contursi kindred mtDNA. Soc. Neurosci. Abstr. 25(2): 1336.
60. 59. Cassarino, D.S., C.P. Fall, R.H. Swerdlow, T.S. Smith, E.M. Halvorsen, S.W. Miller, J.K. Parks, W.D. Parker & J.P. Bennet. 1997. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362: 77-86.
61. + induced oxygen radical formation with mitochondrial enzymes. Free Radical Biol. Med. 15: 181-186.
62. 61. Martilla, R.J., H. Lorentz & U.K. Rinne. 1988. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86: 321-331.
63. 62. Saggu, H., J. Cooksey, D. Dexter, F.R. Wells, A. Lees, P. Jenner & C.D. Marsden. 1989. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53: 692-697.
64. 63. Kalra, J., A.H. Rajput, S.V. Mantha & K. Prasad. 1992. Serum antioxidant enzyme activity in Parkinson's disease. Mol. Cell Biochem. 110: 165-168.
65. 64. Damier, P., E.G. Hirsch, P. Zhang, Y. Agid & F. Javoy-Agid. 1993. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52: 1-6.
66. 65. Dexter, D.T., A.E. Holley, W.D. Flitter, T.F. Slater, F.R. Wells, S.E. Daniel, A.J. Lees, P. Jenner & C.D. Marsden. 1994. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: an HPLC and ESR study. Movement Disorders 9: 92-97.
67. 66. Sanchez-Ramos, J.R., E. Overvik & B.N. Ames. 1994. A marker of oxyradicalmediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3: 197-204.
68. 67. Sheehan, J.P., R.H. Swerdlow, W.D. Parker, S.W. Miller, R.E. Davis & J.B. Tuttle. 1997. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J. Neurochem. 68: 1221-1233.
69. 68. Cassarino, D.S., P.M. Kenney, J.P. Bennett, JR. 1999. Oxidative stress reduces mitochondrial membrane potentials in Parkinson's and Alzheimer's disease cybrids. Soc. Neurosci. Abstr. 25(2): 1336.
70. 69. Trimmer, P.A. 1999. PD cybrids contain inclusion bodies that share antigenic determinants with Lewy bodies. Soc. Neurosci. Abstr. 25(2): 1336.
71. 70. Wooten, G.F. L.J. Currie, J.P. Bennett, J.M. Trugman & M.B. Harrison. 1997. Maternal inheritance in two large kindreds with Parkinson's disease. Neurology 48: A333.
72. 71. Swerdlow, R.H., J.K. Parks, J.N. Davis, D.S. Cassarino, P.A. Trimmer, L.J. Currie, J. Dougherty, S. Bridges, J.P. Bennett, G.F. Wooten & W.D. Parker. 1998. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann. Neurol. 44: 873-881.